ANI Pharmaceuticals (NASDAQ:ANIP) CFO Sells $207,480.00 in Stock

ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) CFO Stephen Carey sold 2,850 shares of the firm’s stock in a transaction that occurred on Monday, August 31st. The shares were sold at an average price of $72.80, for a total transaction of $207,480.00. Following the transaction, the chief financial officer directly owned 171,843 shares of the company’s stock, valued at $12,510,170.40. This represents a 1.63% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

ANI Pharmaceuticals Stock Performance

Shares of ANIP opened at $71.99 on Friday. The company has a quick ratio of 2.41, a current ratio of 2.91 and a debt-to-equity ratio of 0.99. The stock has a market cap of $1.65 billion, a P/E ratio of 15.52 and a beta of 0.45. The business’s 50 day moving average price is $78.89 and its 200-day moving average price is $78.49. ANI Pharmaceuticals, Inc. has a 52 week low of $70.15 and a 52 week high of $99.50.

ANI Pharmaceuticals (NASDAQ:ANIP) last posted its quarterly earnings data on Friday, August 7th. The specialty pharmaceutical company reported $2.21 earnings per share for the quarter, beating analysts’ consensus estimates of $2.04 by $0.17. ANI Pharmaceuticals had a return on equity of 27.37% and a net margin of 11.07%.The company had revenue of $266.04 million during the quarter, compared to analyst estimates of $260.13 million. During the same quarter last year, the company earned $1.80 EPS. The firm’s revenue for the quarter was up 25.8% on a year-over-year basis. ANI Pharmaceuticals has set its FY 2026 guidance at 9.190-9.690 EPS. Equities research analysts anticipate that ANI Pharmaceuticals, Inc. will post 7.83 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently modified their holdings of the business. KBC Group NV bought a new stake in ANI Pharmaceuticals in the 1st quarter worth about $28,000. Advisors Asset Management Inc. bought a new position in ANI Pharmaceuticals during the 1st quarter valued at about $28,000. Hantz Financial Services Inc. lifted its stake in ANI Pharmaceuticals by 70.3% during the 4th quarter. Hantz Financial Services Inc. now owns 603 shares of the specialty pharmaceutical company’s stock valued at $48,000 after acquiring an additional 249 shares during the period. Kemnay Advisory Services Inc. purchased a new stake in shares of ANI Pharmaceuticals during the 4th quarter valued at about $48,000. Finally, State of Wyoming purchased a new stake in shares of ANI Pharmaceuticals during the 2nd quarter valued at about $50,000. 76.05% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

ANIP has been the topic of a number of analyst reports. Zacks Research cut shares of ANI Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Thursday, May 14th. Wall Street Zen lowered shares of ANI Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research note on Saturday, August 8th. Weiss Ratings cut shares of ANI Pharmaceuticals from a “buy (b-)” rating to a “hold (c+)” rating in a report on Tuesday, August 11th. Canaccord Genuity Group dropped their target price on shares of ANI Pharmaceuticals from $91.00 to $90.00 and set a “hold” rating on the stock in a research note on Monday, August 10th. Finally, Guggenheim cut their price target on shares of ANI Pharmaceuticals from $124.00 to $119.00 and set a “buy” rating on the stock in a report on Monday, August 10th. Four equities research analysts have rated the stock with a Buy rating and four have given a Hold rating to the stock. Based on data from MarketBeat.com, ANI Pharmaceuticals has a consensus rating of “Moderate Buy” and a consensus price target of $105.83.

About ANI Pharmaceuticals

ANI Pharmaceuticals, Inc is a United States–based specialty pharmaceutical company focused on the development, manufacturing and commercialization of generic and branded prescription drugs. The company operates as an end-to-end provider, offering services that range from active pharmaceutical ingredient (API) production and formulation development to finished dosage form manufacturing and packaging.

ANI’s product portfolio encompasses injectable and oral therapies across several therapeutic areas, including endocrinology, oncology, pain management and respiratory care.